SCHEMBL3268280

SCHEMBL3268280

NC(=O)Sc1nc(N)nc2c1ncn2Cc1ccccc1F

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 5/20 0.57
ADORA1 P30542 3/20 0.57
CYP2C19 P33261 2/20 0.50
CYP1A2 P05177 2/20 0.50
ALDH1A1 P00352 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2C9 P11712 1/20 0.50
HIF1A Q16665 1/20 0.50
PHLPP2 Q6ZVD8 1/20 0.50
HDAC6 Q9UBN7 3/20 0.49
PDE4A P27815 5/20 0.48
PDE4B Q07343 5/20 0.48
PDE4C Q08493 5/20 0.48
PDE4D Q08499 5/20 0.48
PDE5A O76074 3/20 0.46
PDE1A P54750 3/20 0.46
PDE1B Q01064 3/20 0.46
PDE1C Q14123 3/20 0.46
PDE3B Q13370 2/20 0.45
PDE3A Q14432 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3269795 0.81 ADORA2A (0.64) ADORA2AADORA1HDAC6PDE4APDE4B
SCHEMBL9738574 0.81 ADORA2A (0.66) ADORA2AADORA1HDAC6PDE4APDE4B
SCHEMBL3268278 0.81 ADORA2A (0.60) ADORA2AADORA1CYP2C19CYP1A2ALDH1A1
SCHEMBL9739023 0.76 PDE4A (0.72) ADORA2AADORA1HDAC6PDE4APDE4B
SCHEMBL9738116 0.76 ADORA2A (0.60) ADORA2AADORA1HDAC6PDE4APDE4B
SCHEMBL3269162 0.76 ADORA2A (0.60) ADORA2AADORA1CYP2C19CYP1A2ALDH1A1
SCHEMBL27596754 0.74 ADORA2A (0.55) ADORA2AADORA1ALDH1A1HDAC6PDE4A
SCHEMBL3272538 0.72 ADORA2A (0.56) ADORA2AADORA1HDAC6PDE4APDE4B
SCHEMBL3269399 0.72 ADORA2A (1.00) ADORA2AADORA1ADORA3ADORA2B
SCHEMBL9235491 0.72 PNP (0.70) ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1349857-B1 PURINE DERIVATIVES AS PURINERGIC RECEPTOR ANTAGONISTS VERNALIS RES LTD (GB) 2010-06-16 EP disclosed
US-7452894-B2 Purine derivatives as purinergic receptor antagonists VERNALIS RESEARCH LIMITED (GB) 2008-11-18 US disclosed
US-20060270691-A1 Purine derivatives as purinergic receptor antagonists VERNALIS RESEARCH LIMITED 2006-11-30 US disclosed
US-20040102459-A1 Purine derivatives as purinergic receptor antagonists VERNALIS RESEARCH LIMITED (GB) 2004-05-27 US disclosed
EP-1349857-A1 PURINE DERIVATIVES AS PURINERGIC RECEPTOR ANTAGONISTS VERNALIS RESEARCH LIMITED (GB) 2003-10-08 EP disclosed
WO-2002055521-A1 PURINE DERIVATIVES AS PURINERGIC RECEPTOR ANTAGONISTS VERNALIS RESEARCH LIMITED (GB) 2002-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270691-A1 Purine derivatives as purinergic receptor antagonists CHRNA10, CHRNA5, CHRNA4 ADORA2A 14/4885ADORA1 17/4885CYP2C19 1174/4885
US-20040102459-A1 Purine derivatives as purinergic receptor antagonists OPRL1, CNR1, CNR2 ADORA2A 13/4885ADORA1 28/4885CYP2C19 1406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.